Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data

Hiroshi Deguchi, Yajnavalka Banerjee, Sunia Trauger, Gary Siuzdak, Ewa Kalisiak, José A. Fernández, Linh Hoang, Minerva Tran, Subramanian Yegneswaran, Darlene J. Elias, John H. Griffin

Blood (2015) 126 (13): 1595–1600.

https://doi.org/10.1182/blood-2015-03-636761

Published: 2015

Includes: Supplemental data

Journal Articles

Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics

Hiroshi Deguchi, MD PhD, Yajnavalka Banerjee, PhD, Gary Siuzdak, PhD, Sunia Trauger, PhD, Ewa Kalisiak, PhD, Jose A. Fernandez, MD PhD, Linh Hoang, Minerva Tran, Subramanian Yegneswaran, PhD, Darlene J Elias, MD, John H. Griffin, PhD

Blood (2014) 124 (21): 2797.

https://doi.org/10.1182/blood.V124.21.2797.2797

Published: 2014

Journal Articles

Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.

Subramanian Yegneswaran, PhD, Yajnavalka Banerjee, PhD, Jose A. Fernandez, MD, PhD, Hiroshi Deguchi, MD, PhD, John H. Griffin, PhD

Blood (2010) 116 (21): 1130.

https://doi.org/10.1182/blood.V116.21.1130.1130

Published: 2010

Journal Articles

Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant

Laurent O. Mosnier, Antonella Zampolli, Edward J. Kerschen, Reto A. Schuepbach, Yajnavalka Banerjee, José A. Fernández, Xia V. Yang, Matthias Riewald, Hartmut Weiler, Zaverio M. Ruggeri, John H. Griffin

Blood (2009) 113 (23): 5970–5978.

https://doi.org/10.1182/blood-2008-10-183327

Published: 2009

Includes: Supplemental data

Journal Articles

Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2)

Xia V. Yang, PhD, Yajnavalka Banerjee, PhD, Jose A. Fernandez, MD, PhD, Hiroshi Deguchi, MD, PhD, Xiao Xu, Laurent O. Mosnier, PhD, Rolf T Urbanus, MD, Phillip G deGroot, PhD, Tara C White, Owen J.T. McCarty, PhD, John H. Griffin, PhD

Blood (2008) 112 (11): 695.

https://doi.org/10.1182/blood.V112.11.695.695

Published: 2008

NARROW

Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data

Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics

Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.

Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant

Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2)

Email alerts

ASH Publications

American Society of Hematology

Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data

Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics

Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.

Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant

Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only